Skip to main content
. 2016 Mar 16;4(3):88–93. doi: 10.12998/wjcc.v4.i3.88

Figure 1.

Figure 1

Clinical course of Case 1 of viral breakthrough during the combination treatment with daclatasvir and asunaprevir. RAVs: Resistance-associated variants; HCV: Hepatitis C virus; ALT: Alanine aminotransferase; UDCA: Ursodeoxycholic acid; DCV: Daclatasvir; ASV: Asunaprevir.